Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00351702
Status:
COMPLETED
Last Update Posted:
2024-05-22
First Post:
2006-07-12
Brief Title:
Preventive Therapy for Tuberculosis in HIV Infected Persons
Sponsor:
Tuberculosis Research Centre India
Organization:
Tuberculosis Research Centre India
Study Overview
Official Title:
Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Title Evaluation of efficacy of two different preventive therapy regimens for tuberculosis in HIV infected persons
Phase Phase III trial
Population 650 HIV positive patients without tuberculosis
Number of sites Three
1 Tuberculosis Research centre Chennai
2 Government General Hospital Chennai
3 Government Rajaji Hospital Madurai
Study Duration 36 months
Study Objectives To compare the efficacy of two TB preventive therapy regimens in reducing the incidence of tuberculosis and mortality among HIV-infected persons
Study Design
The study will be a two-armed prospective randomized clinical trial among HIV- positive patients without active tuberculosis Enrolled patients will be assigned to one of the two unsupervised self-administered treatment regimens ie EH for 6 months or INH alone for 3 years At the end of a 3-year follow-up incidence of TB and overall mortality will be compared in each group
Study EndpointsThe primary end point of the study will be development of tuberculosis and the secondary endpoints will include adverse drug reactions and mortality rate
Phase Phase III trial
Population 650 HIV positive patients without tuberculosis
Number of sites Three
1 Tuberculosis Research centre Chennai
2 Government General Hospital Chennai
3 Government Rajaji Hospital Madurai
Study Duration 36 months
Study Objectives To compare the efficacy of two TB preventive therapy regimens in reducing the incidence of tuberculosis and mortality among HIV-infected persons
Study Design
The study will be a two-armed prospective randomized clinical trial among HIV- positive patients without active tuberculosis Enrolled patients will be assigned to one of the two unsupervised self-administered treatment regimens ie EH for 6 months or INH alone for 3 years At the end of a 3-year follow-up incidence of TB and overall mortality will be compared in each group
Study EndpointsThe primary end point of the study will be development of tuberculosis and the secondary endpoints will include adverse drug reactions and mortality rate
Detailed Description:
Study population and enrollment
All HIV positive patients seeking care at one of the study centers above the age of 15 years not suffering from a serious illness non-pregnant and in whom TB was ruled out using the enhanced screening process will be enrolled in the study The consent form for prophylaxis trial will be read to the patients in the local language and written consent will be obtained from willing patients
Randomization and Dosing
All patients enrolled in the prevention trial will be randomized to one of the study groups using a permuted block randomization scheme of four Stratification will be done by Mantoux reading 5mm and 5mm The group assignment list will be generated centrally before the start of trial and sequentially numbered sealed envelopes containing the study group assigned will be prepared independently At the initiation of prophylaxis each patient will be counseled about the importance of taking drugs regularly Patients will be asked to return the empty packets as well as unused tablets at each monthly visit
The treatment regimens in each study group will be as follows
1 Ethambutol 800 mg and Isoniazid 300 mg daily for six months self-administered collected once in fifteen days
2 Isoniazid 300 mg daily for 3 years with fortnightly collection of drugs Subjects in both study groups will receive 10 mg of Pyridoxine daily during treatment
All HIV positive patients seeking care at one of the study centers above the age of 15 years not suffering from a serious illness non-pregnant and in whom TB was ruled out using the enhanced screening process will be enrolled in the study The consent form for prophylaxis trial will be read to the patients in the local language and written consent will be obtained from willing patients
Randomization and Dosing
All patients enrolled in the prevention trial will be randomized to one of the study groups using a permuted block randomization scheme of four Stratification will be done by Mantoux reading 5mm and 5mm The group assignment list will be generated centrally before the start of trial and sequentially numbered sealed envelopes containing the study group assigned will be prepared independently At the initiation of prophylaxis each patient will be counseled about the importance of taking drugs regularly Patients will be asked to return the empty packets as well as unused tablets at each monthly visit
The treatment regimens in each study group will be as follows
1 Ethambutol 800 mg and Isoniazid 300 mg daily for six months self-administered collected once in fifteen days
2 Isoniazid 300 mg daily for 3 years with fortnightly collection of drugs Subjects in both study groups will receive 10 mg of Pyridoxine daily during treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None